Saltar al contenido

Investigación

NEOALTTO

Research

Research

Código Clinicaltrial.gov:
NCT00553358
Estado:
Finalizado
Escenario:
Neoadyuvante
Subtipo tumoral :
HER2+
Fase:
Fase III
Fármaco/Intervención:
Lapatinib y Trastuzumab

Comparación del doble bloqueo de HER2 (lapatinib, trastuzumab) con quimioterapia antes de cirugía versus monoterapia anti-HER2

Ensayo de fase III, aleatorizado, multicéntrico y abierto de lapatinib, trastuzumab y su combinación más paclitaxel como neoadyuvantes en mujeres con cáncer de mama primario HER2 positivo.

Promotor/es

GlaxoSmithKline

Colaborador/es

Breast International Group
SOLTI

Investigador/es principales

José Baselga, MD, PhD

Memorial Sloan Kettering Cancer Center

Holger Eidtmann, MD

University Medical Center, Schleswig-Holstein Campus Kiel

Publicaciones relacionadas

Artículo
Lapatinib with trastuzumab for Her2-positive early breast cancer (NEOALTTO): a randomised, open-label, multicentre, phase 3 trial
Artículo
Factors associated with surgical management following neoadjuvant therapy in patients with primary Her2-positive breast cancer: results from the NEOALTTO phase III trial
Artículo
Circulating tumor cells and response to neoadjuvant paclitaxel and Her2-targeted therapy: a sub-study from the NEOALTTO phase III trial
Artículo
Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial
Artículo
18F-FDGg PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in Her2-positive breast cancer: results from NEOALTTO
Artículo
Lapatinib with trastuzumab for Her2-positive early breast cancer (NEOALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Artículo
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (Her2)-targeted therapies in Her2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Artículo
High Her2 expression correlates with response to the combination of lapatinib and trastuzumab
Artículo
Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in Her2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NEOALTTO trial
Artículo
PIK3CA mutations are associated with decreased benefit to neoadjuvant Her2-targeted therapies in breast cancer
Comunicaciones en congresos
First results of the NEOALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER 2-positive primary breast cancer.
Comunicaciones en congresos
FDG-PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer patients: the NEO-ALTTO study results
Comunicaciones en congresos
The discrepancy between high pathological complete response (pCR) rate and low breast conserving surgery following neoadjuvant therapy: analysis from the NEOALTTO trial
Comunicaciones en congresos
Correlation between circulating tumor cells (CTCS), PET/CT and pCR in primary HER2+ breast cancer, a sub-study from the NEOALTTO trial
Comunicaciones en congresos
FDG-PET/CT for early prediction of response to neoadjuvant anti-HER2 therapies in HER2-positive breast cancer (BC) patients
Comunicaciones en congresos
Effective incorporation of biospecimen collection for translational studies into a phase III trial: the NEOALTTO experience
Comunicaciones en congresos
PI3KCA mutations and correlation with PCR in the NEOALTTO trial (BIG 01-06)
Comunicaciones en congresos
Pattern of rash, diarrhea, and hepatic toxicities secondary to neoadjuvant lapatinib and their association with age and pathological complete response (PCR) in breast cancer (BC) patients: analysis from the NEOALTTO trial
Comunicaciones en congresos
The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in Her2-positive breast cancer. Survival follow-up analysis of NEOALTTO study (BIG 1-06 )
Comunicaciones en congresos
10 (PTEN) evaluation in the NEOALTTO trial (BIG 01-06)
Comunicaciones en congresos
EGFR expression is associated with decreased response from Her2 targeted therapeutics in the neo-adjuvant setting in the NEOALTTO trial
Comunicaciones en congresos
High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NEOALTTO phase III trial
Comunicaciones en congresos
Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNAseq predict response to anti-Her2 treatment in the NEOALTTO trial
Comunicaciones en congresos
Whole exome sequencing of pre-treatment biopsies from the NEOALTTO trial to identify DNA aberrations associated with response to Her2-targeted therapies
Comunicaciones en congresos
Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in Her2 positive breast cancer: results from NEOALTTO (BIG 1-06).
Artículo
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Artículo
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Artículo
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Artículo
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Artículo
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Artículo
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Artículo
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
Artículo
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.
X

En Grupo Solti utilizamos cookies, propias y de terceros, analíticas, publicitarias y de elaboración de perfiles, basadas en hábitos de navegación del usuario, para mejorar la calidad del servicio, medir la audiencia y ofrecerle publicidad que pueda ser de su interés. Puede obtener más información en nuestra Política de Cookies.

Entendemos que acepta el uso de cookies en caso de que siga navegando.

Puede gestionar las cookies y aceptarlas o rechazarlas en el Panel de Configuración.